RET and medullary thyroid gland carcinoma: Whether the median PFS of placebo arm was superimposable to the median PFS observed in the placebo group of the EXAM trial (4.0 months), median PFS obtained with nintedanib is far from the 11.2 months observed with cabozantinib (11) or with the “not estimable” value reported with pralsetinib (8) or selpercatinib (9) in the RET-mutated MTC.